Composition with anesthetic effect of short or long duration for topical use in general

Description

1 / 5 Composition with short- or long-lasting anesthetic effect for general topical use. FIELD OF APPLICATION This descriptive report refers to a Patent Application for an Invention for a general-use anesthetic composition, belonging to the pharmaceutical-cosmetic sector, which is extremely practical and efficient, meeting the conditions to be worthy of the protection now sought. 002 The composition for short or long-lasting anesthetic effect for general topical use, through improvements and the technology employed, aims to develop a prolonged anesthetic composition for pain relief in tattoo sessions and / or aesthetic procedures, basically comprising a first variation of the ointment with the following formula: 05 to 09% lidocaine, 05 to 09% prilocaine, 01 to 03% epinephrine.In a second variation, the ointment has the following formula: 15% to 30% lidocaine and 0.1% to 0.3% epinephrine, standing out in the consumer market due to its differentiated composition and use, offering numerous advantages, among which the main ones are reducing skin sensitivity, allowing the consumer to endure a tattoo session or aesthetic procedure with less discomfort; a simple formulation and efficiency depending on the amount of product applied, representing an evolutionary solution whose practical results indicate a differentiated and effective condition of use. STATE OF THE ART 003 With the sole and exclusive purpose of providing veracity to the preamble of this description, the applicant will now provide, in the following paragraphs, a brief but consistent explanation of the state of the art regarding the problems and inconveniences existing in aesthetic procedures or the application of tattoos on the skin, where it will be possible for a person skilled in the art to recognize its deficient aspects, in order to later clearly identify in the invention now claimed the requirement of Petition 870250007291, dated 01 / 29 / 2025, page 6 / 17 2 / 5 novelty, mandatory under the Industrial Property Law. 004 As is widely known, tattooing is one of the most well-known and celebrated forms of body modification in the world. It is a permanent art form done on human skin that, technically, consists of a subcutaneous application obtained through the introduction of pigments by needles, interpreted by the body as a physical aggression. 005 It is known by people who have already undergone such procedures that all tattoos or cosmetic procedures involve some level of pain. Depending on the location chosen for the tattoo or procedure, the discomfort will be greater or lesser. 006 Over the years, products such as creams and ointments have been developed to provide pain relief during tattoo sessions and / or aesthetic procedures, since many art enthusiasts have high sensitivity and are therefore unable or hindered from undergoing the procedure. 007 The state of the art reveals Brazilian patent PI 09004823, published on 03 / 11 / 2009, entitled COMPOSITIONS FOR PROVIDING AN ANALGESIC EFFECT TO THE SKIN, which describes compositions that include an amine-containing compound, selected from formula I and formula II wherein R~ 1~, R~ 2~, R~ 3~, R~ 4~ and R~ 5~, independently, are selected from the group consisting of hydrogen, C~ 1~-C~ 6~ alkyl, and C~ 1~-C~ 6~ hydroxyalkyl; or a cosmetically acceptable salt thereof; and a sensation-blocking agent, wherein the compositions provide an analgesic effect on the skin when applied to an area of ​​skin exhibiting at least one symptom of itching, pain, stinging, burning, or similar sensations. The analgesic described in this patent does not present the characteristics and innovations of the present application, and has a completely different composition from that proposed in this patent. 008 The state of the art also reveals Brazilian patent BR 10 2019 000964-0, published on 04 / 08 / 2020, which describes a dermocosmetic composition, obtained through a simple preparation process, consisting of biocompatible moisturizing, humectant and nourishing active ingredients, which Petition 870250007291, dated 01 / 29 / 2025, page 7 / 17 3 / 5 guarantee tissue repair, preventing skin irritation and ensuring local adhesion when applying protective film, contributing to the post-tattoo healing process. To this end, the composition consists of the following active ingredients: aluminum sulfate (1); double-distilled vegetable glycerin (2); dexpanthenol (5); an active ingredient consisting of pentylene glycol, glycerin, sodium lactate, lactic acid, serine, urea, sorbitol, sodium chloride, allantoin and water (3) - Hidrovital®, an active ingredient consisting of pentylene glycol, glycerin, sodium lactate, lactic acid, serine, urea, sorbitol, sodium chloride, allantoin and water; and PCANa (4); using grain alcohol (7) and purified water (A) as vehicles; therefore, the composition consists of components with recognized skin repair and hydration activity, thus being indicated for hydration and repair of the skin barrier after the tattooing process.Due to its hydrophilic base, the formulation does not present the drawbacks of products currently on the market, which are generally based on greasy bases that make applying the protective film difficult; or on conventional hydroalcoholic bases, which lack moisturizing and nourishing agents. The analgesic described in this patent does not present the characteristics and innovations of the present application, and has a completely different composition from that proposed in this patent. 009 Despite the excellent application of the products described above, and also of the ointments known on the market for relieving skin pain, many of which are already used in tattooing sessions, these are composed of chemical components, usually in large quantities. 010 In view of the foregoing technical fundamentals, with the passage of time and the accumulation of experience, the facts pointed towards the construction of a novel topical anesthetic composition, presenting several benefits, being quite practical and efficient, where its unique construction eliminates the negative aspects known in the State of the Art, which is presented in this patent. PATENT OBJECTIVE 011 In order to overcome the problems presented, the inventor hereby requests a Patent of Invention, title Petition 870250007291, dated 01 / 29 / 2025, page 8 / 17 4 / 5 COMPOSITION WITH SHORT OR LONG-LASTING ANESTHETIC EFFECT FOR GENERAL TOPICAL USE, which fundamentally aims at developing a prolonged anesthetic composition for pain relief in tattoo sessions and / or aesthetic procedures, standing out in the consumer market due to presenting a differentiated product in terms of its manufacture and use, while also obtaining a low-cost and highly efficient product. 012 With many years in the market, and always seeking innovations and practical solutions to differentiate its products from those of its competitors, the inventor developed this simple and efficient product, capable of overcoming all the limitations and inconveniences reported in the State of the Art in an extremely effective way. 013 According to the present invention, it basically comprises a first variation of the ointment with the following formula: 0.5 to 0.9% lidocaine, 0.5 to 0.9% prilocaine, 0.1 to 0.3% epinephrine. 014 In a second variation, the ointment has the following formula: 15% to 30% lidocaine and 0.1 to 0.3% epinephrine. 015 The main objective proposed by the new anesthetic composition is to reduce the sensitivity of the skin area, allowing the consumer to endure a tattoo session or aesthetic procedure with less discomfort. 016 Another advantage of the product is that it provides a new dermatologically tested formulation that also acts according to the amount used; that is, applying a small amount will have a reduced effect, while applying a large amount will have a greater effect. 017 Another great advantage is the enormous diversification of markets in which the product can be used, such as: in tattoo studios, in the health sector in general clinics, and in aesthetic clinics. 018 It is important to understand that the present Invention Patent presented here is illustrated in a demonstrative and non-limiting manner regarding the application of the details, dimensions, capacities and steps described. It is capable of other modalities and of being practiced or executed in a Petition 870250007291, dated 01 / 29 / 2025, p. 9 / 17 5 / 5 variety of modes, without straying, logically, from the main inventive scope of the object, whose protection is claimed. PREFERRED DESCRIPTION 019 In accordance with the attached drawings, the COMPOSITION WITH ANESTHETIC EFFECT OF SHORT OR LONG DURATION FOR TOPICAL USE IN GENERAL, object of this present Patent of Invention application, basically comprises a first variation of the ointment with the following formula: 05 to 09% lidocaine, 05 to 09% prilocaine, 01 to 03% epinephrine. 020 In a second variation, the ointment has the following formula: 15% to 30% lidocaine and 0.1 to 0.3% epinephrine. 021 Although one embodiment of the invention has been shown and described, other embodiments may be apparent to those skilled in the art. Therefore, it will be understood that the embodiments shown in the drawings and described above are merely for illustrative purposes and are not intended to limit the scope of the invention, which is defined by the claims that follow. Petition 870250007291, dated 01 / 29 / 2025, page 10 / 17

Claims

1 / 1 CLAIMS 1) COMPOSITION WITH ANESTHETIC EFFECT OF SHORT OR LONG DURATION FOR TOPICAL USE IN GENERAL, used to numb the skin before tattooing, micropigmentation, aesthetic procedures in general, characterized by a first variation of the ointment with the following formula: 05 to 09% lidocaine, 05 to 09% prilocaine, 01 to 03% epinephrine. 2) COMPOSITION WITH SHORT- OR LONG-LASTING ANESTHETIC EFFECT FOR GENERAL TOPICAL USE, used to numb the skin before tattooing, micropigmentation, and general aesthetic procedures, according to claim 1, characterized by a second variation of the ointment that has the following formula: 15% to 30% lidocaine and 0.1% to 0.3% epinephrine. Petition 870250007291, dated 01 / 29 / 2025, p. 11 / 17